Shield Therapeutics plc
SHIEF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $15,625 | $7,497 | $4,807 | $3,586 |
| % Growth | 108.4% | 56% | 34% | – |
| Cost of Goods Sold | $7,912 | $3,955 | $2,645 | $2,858 |
| Gross Profit | $7,713 | $3,543 | $2,162 | $729 |
| % Margin | 49.4% | 47.3% | 45% | 20.3% |
| R&D Expenses | $808 | $546 | $298 | $694 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11,392 | $6,432 | $7,455 | $8,322 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$268 | -$139 | -$21 | $0 |
| Operating Expenses | $11,932 | $6,839 | $7,733 | $9,063 |
| Operating Income | -$4,219 | -$3,297 | -$5,570 | -$8,111 |
| % Margin | -27% | -44% | -115.9% | -226.1% |
| Other Income/Exp. Net | -$2,613 | -$846 | -$563 | -$325 |
| Pre-Tax Income | -$6,832 | -$4,142 | -$6,134 | -$8,435 |
| Tax Expense | $115 | $235 | $1 | $43 |
| Net Income | -$6,947 | -$4,377 | -$6,133 | -$8,479 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS | -0.007 | -0.006 | -0.008 | -0.011 |
| % Growth | -17.9% | 28.2% | 31.6% | – |
| EPS Diluted | -0.007 | -0.006 | -0.008 | -0.011 |
| Weighted Avg Shares Out | 1,041,849 | 783,505 | 782,112 | 742,197 |
| Weighted Avg Shares Out Dil | 1,041,690 | 783,474 | 782,056 | 742,186 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $101 |
| Interest Expense | $2,613 | $817 | $563 | $0 |
| Depreciation & Amortization | $248 | $104 | $238 | $48 |
| EBITDA | -$3,971 | -$3,193 | -$5,332 | -$8,063 |
| % Margin | -25.4% | -42.6% | -110.9% | -224.8% |